Aurora (TSX:ACB) Stock Dipped Below $5 and Is Too Cheap to Ignore!

Aurora Cannabis shows precisely how severe the year has been for pot stocks. Approaching an all-time low, let us see if you should still consider the stock.

| More on:
Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aurora Cannabis (TSX:ACB)(NYSE:ACB) shares present a picture of how bad 2019 was for the entire legal marijuana industry in Canada. From reaching remarkable highs of $13.71 towards October 2018, it took ACB very little time to drop to half its value and go down to $6.67 by the end of December.

Things started looking up for the pot stock, as ACB climbed up to $12.83 in March 2019. Much like most of the significant pot companies, the second-largest Canada-based cannabis producer had a lot of growth potential. Similarly, the now $4.96 billion market capitalization company could not deliver profitability, which reflected the promise.

It is safe to say that analysts and investors alike are wary of the overall legal marijuana industry, and Aurora Cannabis is no exception. ACB saw a steep drop in value from its 52-week high from March 15, 2019, to lose 62.43% and come down to the current price of $4.82 a share. The question is, does the below $5 valuation make ACB a good buy?

Growers causing growers problems

A significant reason why the wider legal marijuana industry could not deliver profitability is owing to the illegal pot industry. Illegal growers have to worry about little more than the costs of growth and distribution. Legal producers have a slew of expenses to worry about, and on top of that, they face regulatory restrictions and quality standards.

The costs these companies face end up affecting the prices of products that end consumers buy. The demand for recreational marijuana is high, but many consumers prefer to buy cheaper products from illegal growers. Beyond the unfair competition to meet demand, scandals riddling the industry also drive a lot of potential customers away, making life tougher.

More promises

With Cannabis 2.0, Canada passed another wave of laws legalizing further cannabis-related products, such as vapes, concentrates, and edibles. The market for these products presents a better future for pot producers since they entail higher profit margins for the significant pot companies. The announcement was as recent as October 17, 2019, and these products will not be available for retail until at least mid-December.

Aurora Cannabis is among the several companies eyeing Cannabis 2.0 as an opportunity to make right on its promises. The company plans to use this as a means to reach better valuations and sustain robust growth in revenue.

Terry Booth, Aurora’s CEO, stated that the company has made industry-leading capacity to produce cannabis. He claims that ACB’s consumer research and retail distribution bench strength will help the company launch the next-gen cannabis products in the Canadian markets. Aurora has plans to leverage the broader market opened up by Cannabis 2.0.

Foolish takeaway

I have said it before, and I will repeat it: ACB has a lot of potential for growth. The introduction of next-generation products, courtesy of Cannabis 2.0, could likely present Aurora the adrenaline shot that the company needed. However, as I also said, pot companies are struggling to compete with the illegal weed market.

If you are interested in cannabis stocks, I believe that taking a little bit of risk and placing your faith in Aurora could turn out to be great. I would not, however, suggest investing more than what you are willing to lose.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »